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18F-FLT Positron Emission Tomography/Computed Tomography

Imaging in Pancreatic Cancer: Determination of Tumor Proliferative
Activity and Comparison with Glycolytic Activity as Measured by
18F-FDG Positron Emission Tomography/Computed Tomography
Imaging
Pankreas Kanserinde 18F-FLT Pozitron Emisyon Tomografi/Bilgisayarlı Tomografi
Görüntülemesi: Tümör Çoğalma Hızının Belirlenmesi ve 18F-FDG Pozitron Emisyon
Tomografi/Bilgisayarlı Tomografi ile Ölçülen Glikolitik Aktivite ile Karşılaştırılması
Senait Aknaw Debebe1, Mohammed Goryawala2, Malek Adjouadi2, Anthony J. Mcgoron1, Seza A. Güleç3
1Florida
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Abstract
Objective: This phase-I imaging study examined the imaging characteristic of 3’-deoxy-3’-(18F)-fluorothymidine (18F-FLT) positron
emission tomography (PET) in patients with pancreatic cancer and comparisons were made with (18F)-fluorodeoxyglucose
(18F-FDG). The ultimate aim was to develop a molecular imaging tool that could better define the biologic characteristics
of pancreas cancer, and to identify the patients who could potentially benefit from surgical resection who were deemed
inoperable by conventional means of staging.
Methods: Six patients with newly diagnosed pancreatic cancer underwent a combined FLT and FDG computed tomography
(CT) PET/CT imaging protocol. The FLT PET/CT scan was performed within 1 week of FDG PET/CT imaging. Tumor uptake of
a tracer was determined and compared using various techniques; statistical thresholding (z score=2.5), and fixed standardized
uptake value (SUV) thresholds of 1.4 and 2.5, and applying a threshold of 40% of maximum SUV (SUVmax) and mean
SUV (SUVmean). The correlation of functional tumor volumes (FTV) between 18F-FDG and 18F-FLT was assessed using linear
regression analysis.
Results: It was found that there is a correlation in FTV due to metabolic and proliferation activity when using a threshold
of SUV 2.5 for FDG and 1.4 for FLT (r=0.698, p=ns), but a better correlation was obtained when using SUV of 2.5 for both
tracers (r=0.698, p=ns). The z score thresholding (z=2.5) method showed lower correlation between the FTVs (r=0.698, p=ns)
of FDG and FLT PET.
Conclusion: Different tumor segmentation techniques yielded varying degrees of correlation in FTV between FLT and FDGPET images. FLT imaging may have a different meaning in determining tumor biology and prognosis.
Keywords: 18F-fluorothymidine, 18F-fluorodeoxyglucose, positron emission tomography/computed tomography, pancreatic
cancer imaging, image processing, tumor proliferative activity, tumor glycolytic activity
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Öz
Amaç: Bu faz I çalışma 3’-deoxy-3’-(18F)-fluorothymidine (18F-FLT) pozitron emisyon tomografisi (PET) görüntülemesinin
pankreas kanseri hastalarındaki karakteristiklerini araştırmış ve sonuçlarını (18F)-fluorodeoxyglucose (18F-FDG) görüntülemesi
ile karşılaştırmıştır. Bu çalışmadaki nihai amaç, pankreas kanserinin biyolojik özelliklerini tanımlayan ve pankreas kanseri
hastaları arasında standart anatomik görüntüleme yöntemleri ile cerrahi tedavi imkanı olmadığı sonucuna varılan hastalarda
cerrahi endikasyonlarının ve sınırlarının yeniden tanımlanmasını sağlayacak bir moleküler görüntüleme yöntemi geliştirmektir.
Yöntem: Yeni teşhis almış ve hiçbir tedavi görmemiş altı hasta bir hafta ara ile FLT ve FDG bilgisayarlı tomografi (BT) PET/
BT çalışmasına alındı. Tümör radyofarmasötik tutulumu tespit edilerek değişik yöntemlerle karsılaştırıldı. İstatistiki eşikleme (z
skoru=2,5), sabit standart tutulum değeri standardized uptake value (SUV) olarak 1,4 ve 2,5, ve maksimum SUV değerinin
%40’ı düzeyinde eşikleme yöntemleri denendi. FLT ve FDG ile fonksiyonel tümör hacmi hesaplamaları yapıldı ve ilişkileri lineer
regresyon analizi ile araştırıldı.
Bulgular: FDG için 2,5 SUV ve FLT için 1,4 SUV değerleri kullanıldığında, FDG ve FLT fonksiyonel tümör hacimleri arasında
bir korelasyon bulundu (r=0.698, p=ns). Her iki radyofarmasötik için 2,5 SUV değeri eşik alındığında ise fonksiyonel tümör
hacimleri arasında daha iyi bir korelasyon saptandı (r=0.698, p=ns). Z skoru eşikleme yöntemiyle FLT ve FDG fonksiyonel tümör
hacimleri arasında zayıf bir ilişki tespit edildi (r=0,698, p=ns).
Sonuç: Değişik tümör segmentasyon yöntemleri FLT ve FDG fonksiyonel tümör hacimleri arasında değişik derecelerde
korelasyon gösterdi. FLT görüntülemesi tümör biyolojisinin belirlenmesinde farklı bir anlamı ve prognostik değeri bulunabilir.
Anahtar kelimeler: 18F-fluorothymidine, 18F-fluorodeoxyglucose, pozitron emisyon tomografisi/bilgisayarlı tomografi,
pankreas kanseri görüntülemesi, görüntü analizi, tümör proliferatif aktivitesi, tümör glikolitik aktivitesi

Introduction

(12). Actually little 18F-FLT is accumulated in DNA, it is rather
retained intracellularly after phosphorylation by thymidine
kinase 1. This is very much analogous to the imaging of the
glucose pathway with 18F-FDG after trapping by hexokinase.
Both compounds therefore reflect accumulation by transport
and subsequent activation by the first step in the utilization
pathways. However, 18F-FLT does not reflect the whole of
DNA synthesis just as 18F-FDG does not reflect the whole of
glucose use.
In this study, we examined the imaging characteristics
of pancreatic cancer patients to determine the correlation
between the metabolic and proliferative activity of pancreatic
cancer using FDG and FLT PET images, respectively. The
parameters of interest were functional tumor volume (FTV),
Total glycolytic index (TGI) and Total proliferative index (TPI).
FTV, TGI and TPI were determined from both FDG and FLT
PET images. These parameters measure the metabolic and
proliferation activity of tumors using FDG and FLT PET/CT
images, respectively, which have clinical value in the assessment
of tumor biology, prognosis, response to treatment evaluation,
and patient selection for therapeutic interventions (4).

Pancreatic cancer (ductal adenocarcinoma) accounts
for approximately 36,800 deaths per year in United States
(1). The majority of patients present in the late stages of
the disease with locally advanced or metastatic tumors,
among which only 10 to 20% of patients are candidates
for resection and hence have any potential for cure. The
signs and symptoms of pancreatic cancer vary from vague,
nonspecific abdominal complaints to severe jaundice and
the diagnosis can often be difficult, especially in the early
stages (2). Despite improvements in diagnostic technology
and development of new systemic therapy agents, the
prognosis of the disease has not shown much improvement.
Surgical resection is the only potential curative treatment
available for patients with pancreatic cancer (1).
(18F)-fluorodeoxyglucose (FDG) positron emission
tomography (PET)/computed tomography (CT) PET/CT
has now become a standard imaging technique for most
cancers and the majority of cancers exhibit increased glucose
metabolism resulting in high concentration of 18F-FDG in
lesions. FDG-PET can change the management of pancreatic
cancer by revealing unsuspected metastases to liver, bone
and lungs, thereby avoiding the morbidity and mortality of
unnecessary surgical interventions (3). Proliferative activities of
tumors are known to correlate with prognosis (4). Numerous
markers have been described to predict the biological behavior
of tumors and outcomes following surgical and medical
treatment. Ki-67 is a nuclear antigen present only in the nuclei
of proliferating cells and Ki-67 immunohistochemistry has
been used to evaluate tumors’ proliferative activity (4,5,6).
Clinical evaluation and quantification of proliferative activity
and tumor invasiveness can be performed using 3’-deoxy3’-(18F)-fluorothymidine (18F-FLT) PET imaging (7,8,9,10,11).
18F-FLT works as a terminator of the growing DNA chain

Materials and Methods
Inclusion Criteria
Patients with pancreatic and periampullary tumors were
identified by pathological examination. Those who were
potential candidates for the trial were further assessed
for eligibility. Inclusion criteria were: clinically diagnosed
pancreatic cancer (newly diagnosed as well as those under
treatment), age ≥18, ability and willingness to give a
written consent, life expectancy >3 months and Karnofsky
performance status ≥70. Patients with age <18, inability or
unwillingness to give a written consent, life expectancy <3
months, Karnofsky performance status <70, pregnant or
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estimate the volume of the segmented pancreas. Once the
pancreas was segmented from the two images, different
thresholding techniques were applied to find the FTVs. We
have used statistical and SUV threshold techniques.
Our aim in this study was not to validate different tumor
delineation methods, but rather to determine the FTV, TGI
and TPI relationships due to the uptake of 18F-FDG and
18F-FLT by using well practiced fixed threshold methods.

nursing women (urine pregnancy test was performed prior
to the investigational radiotracer injection) and individuals
allergic to FLT were excluded.
Patient Characteristics
Six patients fulfilling the inclusion criteria were enrolled
in the study of which two were females and four were
males (median age of 61.5 and range 56-71 years). The
demographics of the patients with the estimated anatomic
pancreatic volumes are presented in Table 1. The anatomic
pancreatic volumes are estimated by outlining the pancreas
on abdominal CT images by an expert radiologist.
Positron Emission Tomography/Computed
Tomography Imaging
The study was performed under a Food and Drug
Administration approved Investigational New Drug and
after institutional review board review and approval. The
3’-18F-fluoro-3’-deoxy-L-thymidine used in this trial was
obtained from Cardinal Health 414, LLC. Administered
activities both for 18F-FLT and 18F-FDG were 10±1 mCi with
post injection imaging point of 60±15 minutes. Images
were obtained with 16-slice Siemens PET/CT camera. The
scanning parameters for the CT imaging were 140 kVp,
80mA, 0.5s rotation time and 512×512-pixel matrix. CT
image sizes range from 512x512x186 to 512x512x273.
PET image sizes range from 168x168x186 to 168x168x273
with voxel size of 4.0627x4.0627x4 mm3.
Methods for Finding Functional Tumor Volumes
As a first step, FLT PET images were manually coregistered with FDG PET/CT images using AMIDE software,
a free tool for viewing, analyzing and registering volumetric
medical imaging data sets. Next, an experienced board
certified radiologist used the region of interest (ROI)
method to isolate the pancreas from CT images of the FDG
PET/CT. After this point, MATLAB® (The MathWorks Inc.)
was used to perform automatic tumor segmentation. The
Binary masks from the ROIs of CT images were mapped to
the co-registered FDG PET and FLT PET images to segment
the pancreas. Third party interactive application software
called ScanIPTM was used in 3D medical image analysis to

Statistical Tumor Segmentation
The segmented pancreas was normalized by z score
transformation using equation 1, where ‘x’ is the pixel
intensity value, and ‘μ’ and ‘σ’ are the mean and standard
deviation of the segmented pancreas images, respectively.
The z score transformation procedure for normalizing
data is a familiar statistical method in neuroimaging
and psychological studies (3). This method converts the
original pixel intensity image to a probability map that
represents deviations from the normal using voxel-by-voxel
comparison, which facilitates image interpretation.

The z score, which transforms the image into a
statistical parametric map, was calculated for each
pixel. Threshold of z≥2.5 was then applied which only
highlights those pixels which can confidently be labelled
as active, i.e. those areas which deviate significantly
from the normal (13). Using this technique considers
the low tumor to background ratio by comparing each
pixel to the surrounding pixels through deviation from
the mean.
Standardized Uptake Value (SUV) Based Tumor
Segmentation
SUV provides biological and functional activity of a tumor
(14). Quantification of FLT with SUV provides information
about cells undergoing active proliferation while SUV of
FDG provides information on increased glucose metabolism.
SUVs were calculated with mathematical expression shown
in equation 2.

Table 1. Patient characteristics
Patient
no

Age
(years)

Gender

1

71

M

2

67

F

Volume of
Pancreas (ml)

SUVmax
18F-FDG

18F-FLT

206

33.21

16.52

143

5.85

2.60

3

57

M

248

5.45

12.25

4

56

M

120

5.30

9.17

5

62

M

107

1.32

3.12

6

61

F

96.3

3.46

5.12

Different SUV thresholds were used to investigate tumor
localization; SUV of 1.4, 2.5, 40% SUVmax and SUVmean.
SUVmax and SUVmean refer to the maximum and mean
SUV values from each individual patient’s PET images.
One of the methods was using 40% of the maximum SUV
uptake for each patient to segment tumor. Each patient
has different maximum SUV uptakes for the radiotracer
type, thus the amount of threshold varies accordingly.
From the maximum SUVs, 40% of this value (40% SUVmax)

M: Male, F: Female, 18F-FDG: 2-deoxy-2-(18F)-fluoro-D-glucose, 18F-FLT: 3’-18F-fluoro3’-deoxy-L-thymidine, FDG: Fluorodeoxyglucose, FLT: Fluorothymidine
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Results

was applied as a threshold to segment tumors. The same
concept was used when the mean SUV (SUVmean) uptake
for tumor segmentation was applied. Table 1 shows the
maximum SUVs for each patient.

Results of FTVs (ml) using the different tumor segmentation
methods on 18F-FDG and 18F-FLT PET images are presented
in Table 2 (A) and (B) respectively. Linear regressions were
performed between estimated FTV from 18F-FDG and 18F-FLT
PET for the five different thresholding techniques shown in
Figure 1. Correlation coefficients (r), t and p values of the
linear regression were reported. Analyses were performed
two-sided at a 5% level of significance. Figure 2 shows the
3D rendered images of the pancreas and segmented tumors
using the five different threshold techniques for patient 3.
FDG and FLT PET images with average maximum
SUV uptake of 9.1 (median 5.38, range 1.32-33.21) and
8.1 (median 7.15, range 2.6-16.52), respectively, were
analyzed. Results showed a correlation in FTV due to
metabolic and proliferation activity. Using a threshold of
SUV 2.5 for FDG and 1.4 for FLT, a correlation coefficient
(r) of 0.9606 (t value=7.16, p value <0.05) was found. A
slightly better correlation was found with SUV of 2.5 for
both tracers with of r=0.973 (t value=8.46, p value <0.05).
The p values (5% significance level) from the two SUV
methods strongly support that there is a correlation in FTV
from 18F-FDG and 18F-FLT PET scans.

Functional Tumor Volume Measurement
The voxels, which exceed the applied threshold value,
were counted to find the FTV using equation 3 where AV is
the active voxel that remained after applying the threshold.
Volume of a voxel was 4.0627x4.0627x4 mm3. The FTVs
for 18F-FLT and 18F-FDG were then assessed using linear
regression analysis.

Total Glycolytic and Total Proliferative Index
Measurements
The TGI/TPI is the product of functional volume and
tumor SUVmax. The FTV were multiplied with the respective
SUVmax of the patient.

Table 2A. Estimated pancreas tumor volumes using (A) 18F-FDG PET/CT Imaging
Patient no

z score
(z=2.5)

SUV based
(FDG=2.5, FLT=1.4)

SUV based
(FDG=2.5, FLT 2.5)

40% SUVmax

SUVmean

1

30.90

126.83

126.83

8.06

59.82

2

29.91

11.36

11.36

13.60

57.57

3

76.39

104.65

104.65

142.28

117.12

4

11.16

5.74

5.74

10.70

52.49

5

20.34

0.00

0.00

33.01

30.12

6

20.86

2.25

2.25

32.42

42.58

Average

31.59±21.09

41.81±52.79

41.81±52.79

40.01±46.80

59.95±27.45

18F-FDG:

2-deoxy-2-(18F)-fluoro-D-glucose, PET/CT: Positron emission tomography/computed tomography, SUV: Standardized uptake value,
FDG: Fluorodeoxyglucose, FLT: Fluorothymidine, Averages values are expressed as mean ± SD

Table 2B. Estimated pancreas tumor volumes using (B) 18F-FLT PET/CT Imaging
Patient no

z score
(z=2.5)

SUV based
(FDG=2.5, FLT=1.4)

SUV based
(FDG=2.5, FLT 2.5)

40% SUVmax

SUVmean

1

20.53

146.04

67.21

9.44

63.78

2

27.60

18.68

0.20

33.74

60.87

3

25.42

95.14

62.00

31.69

57.90

4

8.06

38.43

15.25

9.71

17.69

5

12.54

15.12

2.05

20.40

25.35

6

12.74

34.60

12.94

19.41

33.94

Average

17.82±7.18

58.00±47.34

26.61±27.44

20.73±9.49

43.26±18.29

18F-FLT:

3’-18F-fluoro-3’-deoxy-L-thymidine, PET/CT: Positron emission tomography/computed tomography, SUV: Standardized uptake value, FDG: Fluorodeoxyglucose,
FLT: Fluorothymidine, Averages values are expressed as mean ± SD
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experience of the nuclear physician and the contouring
protocol used. Thureau et al. (15) has suggested using a
fixed threshold of SUV 1.4 for 18F-FLT uptake due to the low
tumor-to-background ratio in PET images of lung cancer.
In addition, it was also demonstrated that using SUV of
1.4 gives a similar result as the method used by physicians
to delineate tumors. It is also explained in the literature
that the difference in tumor volumes using different SUV
thresholds to segment 18F-FDG uptake was insignificant.
Han et al. (16) also concluded that SUV cutoff of 1.4 for
18F-FLT PET/CT and SUV of 2.5 for 18F-FDG PET/CT provided
the best estimate of gross tumor volume. Hellwig et al.
(17) demonstrated that SUV of 2.5 thresholds for 18F-FDG
gives a high overall accuracy for clinical images. In our
study, SUV cutoff values that showed to be reproducible
were used for tumor segmentation. The resulting volumes

Strong correlation between TPI and TGI was found
using 40% of SUVmax, r of 0.9977 (t value=29.37, p<0.05).
The 2nd best correlation between TPI and TGI was observed
when threshold of SUV 1.4 for FLT and 2.5 for FDG used
with r=0.9427(t value=5.65, p value <0.05).
The z score threshold (z=2.5) method showed
a moderate correlation between FTVs (r=0.698,
t value=1.95, p value=ns), and TGI and TPI (r=0.89,
t value=3.9, p value <0.05) between the two images.
The p values support the null hypothesis that there is no
correlation between the FTVs of FDG and FLT PET images
with z score method.

Discussion
There is no universally validated technique for tumor
delineation, and manual segmentation is biased by the

Figure 1. Functional tumor volume relationships using (A) z score thresholding, (B) SUV cutoffs of 2.5 for FDG and 1.4 for FLT (C) SUV cutoffs of 2.5 for
both FDG&FLT (D) 40% of SUVmax thresholding (E) SUVmean threshold
FDG:Fluorodeoxyglucose, FLT: Fluorothymidine
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from 18F-FDG and 18F-FLT PET images were compared for
correlation.
In our study, the FLT PET images demonstrated
physiologic uptake in the liver and bone marrow. The activity
in the normal pancreatic tissue was at the background
level. FLT uptake in the tumors was at variable intensity
and did not encompass the entirety of the FDG-positive
regions in the tumor’s topography. Determining FTV from
FLT PET images is challenged by partial volume effect (in
small tumors), and is subject to errors from manual tumor
segmentation that might result in underestimation. These
drawbacks have been explained as a reason for negative
results in FLT PET scans (18). The FTV from FDG PET images
could also be potentially challenged by the enhancement
of FDG activity from a peritumoral inflammatory response.
Thus, a technique that is ideal for FDG images might not
necessarily be applicable to FLT images. To address these
technical difficulties, we used semiautomatic segmentation

methods. The primary aim of this study was to assess and
compare the topography and size of FTV from proliferation
(FLT PET) and metabolic (FDG PET) images.
In this study, the pancreas was first segmented from
18F-FDG CT scans by an experienced radiologist. The
segmented pancreas was then mapped to co-registered
18F-FDG and 18F-FLT PET images. Different thresholding
techniques were applied to automatically segment tumors
from the PET scans.
We used two major methods; statistical and SUV methods.
To our knowledge, this study is the first to use a statistical
(z score) and fixed SUV thresholds on FLT and FDG PET/CT
images of pancreatic cancer in tumor segmentation. The use
of z score threshold considers all pixels inside the pancreas
and delineates only those pixels that deviate considerably
from the mean activity inside the pancreas. In the case of FLT
PET images that have very low contrast, this method provides
an excellent way to differentiate between background and
tumor pixel intensities. Z scores on FLT images take into
consideration the overall organ uptake since not every organ
has similar cell proliferation rates. This method might not
provide an alternate choice for FDG PET images where tumor
to background uptake is well segregated.
The SUV cutoffs (2.5, 1.4, 40% SUVmax and SUVmean)
presented here to segment tumor volumes have been
tested to be reproducible in tumor volume delineation
(15,17,19). We have found different FTVs from FDG and
FLT PET images, which might result in different treatment
planning and different dose delivery if either of the two
tracers is used for diagnostics workup. This might imply
that giving a treatment solely based on FLT or FDG uptake
might be misleading suggesting that incorporating the two
images can be beneficial in treatment planning.
There is a satisfactory FTV correspondence between FDG
and FLT PET when SUV cutoffs of 2.5 and 1.4, respectively,
are used for tumor segmentation. The correlation between
TGI and TPI is seen to be high when a threshold of 40%
of SUVmax is used but this method also gave the highest
probability of false prediction.
Though the volumes delineated as a tumor from the
two images do not always occur in the same place of the
pancreas, our study showed that FTVs from 18F-FDG and
18F-FLT PET images do have correlation. In most patients,
it was observed that tumors segmented from FLT PET
images occur at the head of the pancreas (Figure 2).
Thureau et al. (15) postulated that proliferative volume
should not be greater than metabolic volume. In our study,
the z score method yielded higher tumor volumes from
18F-FDG than 18F-FLT PET images in all patients unlike the
SUV methods where this result was variable from patient
to patient.
In conclusion, the FTVs correlation seen between
FDG and FLT PET scans depends on the type of tumor
segmentation technique used. SUV based thresholds
showed correlations in the FTVs but z score method showed
no correlations of FTVs between FDG and FLT PET scans.

Figure 2. 3D rendered volume of pancreas (red) and tumor volume
delineated based on the uptake of only FDG (yellow) (left), and FDG and
FLT (pink) superimposed (right) for patient 3 using (a)-(b) z score, (c)-(d)
SUV of 2.5 (FDG) & 1.4 (FLT), (e)-(f) SUV of 2.5 for both tracers, (f)-(g) 40%
SUVmax and (h)-(i) SUVmean thresholding
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Conclusions

8.

Different tumor segmentation techniques yielded varying
degree of correlation in functional tumor values between
FLT and FDG PET images. The statistical threshold technique
showed higher tumor volumes from FDG images than from
FLT PET images in all patients. Due to the limited number of
patients and the lack of a gold standard, further investigation
is required to fully appreciate correlations in tumor topography
and size between 18F-FDG PET and 18F-FLT PET images.
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